Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program

Autor: Leigh Perreault, Edward S. Horton, Kieren J. Mather, Marinella Temprosa, George A. Bray, Jonathan Krakoff, Ronald B. Goldberg, Neil H. White, Santica M. Marcovina, Lisa Mele, Trevor J. Orchard, Abbas E. Kitabchi
Rok vydání: 2016
Předmět:
Male
Endocrinology
Diabetes and Metabolism
Saturated fat
030204 cardiovascular system & hematology
Metabolic equivalent
Cohort Studies
Impaired glucose tolerance
0302 clinical medicine
Endocrinology
Risk Factors
Weight loss
Diet
Fat-Restricted
Middle Aged
Combined Modality Therapy
Metformin
Cardiovascular Diseases
Female
lipids (amino acids
peptides
and proteins)
Adiponectin
medicine.symptom
medicine.drug
medicine.medical_specialty
Diet
Reducing
030209 endocrinology & metabolism
Motor Activity
Prediabetic State
03 medical and health sciences
Insulin resistance
Double-Blind Method
Diabetes mellitus
Internal medicine
Weight Loss
medicine
Humans
Hypoglycemic Agents
Life Style
business.industry
Cholesterol
HDL
nutritional and metabolic diseases
Overweight
medicine.disease
United States
Diabetes Mellitus
Type 2
sense organs
business
Biomarkers
Follow-Up Studies
Zdroj: Metabolism. 65:764-775
ISSN: 0026-0495
DOI: 10.1016/j.metabol.2015.11.011
Popis: Objective In addition to slowing diabetes development among participants in the Diabetes Prevention Program (DPP), intensive lifestyle change and metformin raised HDL-cholesterol (HDL-C) compared to placebo treatment. We investigated the lifestyle and metabolic determinants as well as effects of biomarkers of inflammation, endothelial dysfunction and coagulation and their changes resulting from lifestyle and metformin interventions on the increase in HDL-C in the DPP. Methods The effects of a 1 year period of intensive lifestyle change aimed at achieving 7% weight loss or metformin 850 mg twice daily versus placebo on HDL-C were assessed in 3070 participants with impaired glucose tolerance, and on HDL particle concentration (HDL-P) and size in a subgroup of 1645 individuals. Treatment-associated changes in lifestyle and metabolic factors as well as in novel biomarkers were investigated for their associations with change in HDL-C using multiple regression analysis. Results After adjusting for BMI, insulin resistance, glycemia, dietary saturated fat, alcohol intake, physical activity and nine different biomarkers, only adiponectin accounted for the effect of intensive lifestyle change on HDL-C via an increase in large HDL-P. By contrast baseline and change in BMI and tissue plasminogen activator levels attenuated the effect of metformin on HDL-C, with adiponectin having no specific effect. Conclusion While both lifestyle and metformin interventions used to prevent diabetes increase HDL-C, the mechanisms involved differ between the two treatments and may have consequences for future risk of cardiovascular disease.
Databáze: OpenAIRE
Externí odkaz: